MAPK6 and lung carcinoma: Furthermore, ERK3 phosphorylates and regulates the phosphodiesterase activity of TDP2, which has been shown to modulate DNA damage response in lung cancer cells, resulting in chemoresistance to topoisomerase2 inhibitors [23].